

ASX RELEASE

31 August 2020

### **Amplia Appoints Dr Mark Devlin as Chief Scientific Officer**

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce it has appointed Dr Mark Devlin as Chief Scientific Officer. Mark will formally commence this role on 31 August 2020.

As Biology Leader of the Cooperative Research Centre (CRC) for Cancer Therapeutics, Mark was directly involved with the programs that resulted in the initial discovery and development of Amplia’s proprietary Focal Adhesion Kinase (FAK) inhibitor drugs AMP945 and AMP886. He has continued to play an important and active role as a scientific advisor to the company since it was established as a publicly listed company via its acquisition by Innate Therapeutics in May 2018.

Mark has held a number of roles involved in drug discovery and development including a decade at the Peter MacCallum Cancer Centre as part of the CRC for Cancer Therapeutics. In addition to the FAK inhibitors that Amplia is developing, Mark and his team were involved in two oncology programs at the CRC that were licensed to Merck Sharp & Dohme and Pfizer in deals with a combined headline value of US\$960M including upfront payments of close to US\$30M. Most recently, Mark was Chief Executive Officer of CTxONE, a commercial development partner of the CRC for Cancer Therapeutics. Mark holds a PhD in Pharmacology from the University of Melbourne, a Graduate Diploma in Drug Development from the University of New South Wales, and an MBA from Melbourne Business School.

“Mark has been a highly valued advisor to Amplia since its inception and it is exciting to be at a stage where we can finally bring him on board as Chief Scientific Officer”, said Chief Executive Officer John Lambert. “With the first clinical trial of AMP945 about to commence and with a comprehensive program of non-clinical studies to manage, we are delighted that Mark has agreed to formally join the Amplia team at this time. Further, it is increasingly clear from the published literature that FAK is continuing to gain traction as an important drug target for a number of diseases. Having Mark’s input in identifying and developing the most attractive opportunities for Amplia’s drugs, from both a clinical and commercial perspective, will be invaluable.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

#### **For Further Information**

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Level 29, 55 Collins Street, Melbourne VIC 3000

Email [info@ampliatx.com](mailto:info@ampliatx.com)

[www.ampliatx.com](http://www.ampliatx.com)